Literature DB >> 32808741

Cerebral protection in left atrial appendage closure in the presence of appendage thrombosis.

Giacomo G Boccuzzi1, Andrea Montabone1, Fabrizio D'Ascenzo2, Francesco Colombo1, Fabrizio Ugo1, Simone Muraglia3, Ole De Backer4, Luis Nombela-Franco5, Felix Meincke6, Patrizio Mazzone7.   

Abstract

BACKGROUND: Presence of thrombus in the left atrial appendage (LAA) remains a severe contraindication to the percutaneous left atrial appendage closure procedure (LAAC), due to increased embolic risk. Recently, the experience developed in cerebral protection device in transcatheter aortic valve implantation (TAVI) procedure was translated in LAAC to address this issue. AIM: To evaluate efficacy and safety of Sentinel cerebral protection system (CPS) in supporting LAAC in real-world patient with persistent LAA thrombus. METHODS AND
RESULTS: The study retrospectively enrolled consecutive patients with non-valvular atrial fibrillation (NVAF) and thrombus in LAA who underwent LAAC supported by Sentinel CPS in seven European high-volume centres. Twenty-seven patients were included with a median age of 69.1 ± 9.7 years old, with median CHA2 DS2 -VASc and HAS-BLEED scores 3 [2-5] and 3 [2.75-4], respectively. Technical and procedural success was achieved in all patients. No periprocedural TIA, stroke, or supra-aortic trunks dissection was recorded.
CONCLUSIONS: In this multicenter registry, LAAC supported by Sentinel CPS in patients with LAA persistent thrombus seems to be a safe and efficacious treatment.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  cerebral protection device; left atrial appendage

Year:  2020        PMID: 32808741     DOI: 10.1002/ccd.29161

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  1 in total

1.  Recurrent embolisms despite adequate anticoagulant therapy in a patient with prosthetic heart valves and atrial fibrillation: a case report.

Authors:  Alexander Marschall; Diego Rodriguez Torres; Andrea Rueda Liñares; David Martí Sánchez
Journal:  Eur Heart J Case Rep       Date:  2021-07-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.